CP-067 Use of validated care quality indicators to identify improvements in hiv pharmaceutical care. (24th March 2015)

• Record Type: Journal Article
• Authors: Lopez Martin, C; Arenas, J; Nieto, M; Robustillo, A; Morillo, R; Aguilar, E; Rios, E; Garrido, M; Faus, V; Tortajada, B
• Is Part Of: European journal of hospital pharmacy. Volume 22(2015)Supplement 1
• Page Start: A26
• Page End: A27
• Publication Date: 2015-03-24
• Subjects: Pharmacy -- Periodicals; Hospital pharmacies -- Periodicals; 615.1
• DOI: 10.1136/ejhpharm-2015-000639.63
• Languages: English
• ISSNs: 2047-9956

Abstract

Abstract : Background: Care quality indicators are used to quantify quality of care. The Spanish HIV group (GESIDA) has developed care quality indicators for the care of persons infected by HIV/AIDS, some of them related to pharmaceutical activities. Purpose: To determine the compliance with GESIDA indicators and identify areas in which to improve HIV pharmaceutical care. Material and methods: Prospective multicentre study. Inclusion criteria: treatment-naïve patients beginning antiretroviral therapy in 2012 and 2013, 48 weeks of treatment and patient monitoring in pharmaceutical care consultations of the centres involved (PSITAR cohort). The care quality indicators were obtained from the GESIDA consensus document/National AIDS Plan on antiretroviral treatment in adults (2014). Results: 102 patients were studied, 86.3% male, mean age of 39.4 years (SD 11.79). At the beginning of the treatment the median viral load was 69, 700 and mean CD4 was 316 (SD 216); in 57% of patients it was <350. 5.8% of patients showed resistance to any treatment. The most common treatments were tenofovir, emtricitabine and efavirenz combination (44%), darunavir, ritonavir, tenofovir, and emtricitabine combination (10%) and tenofovir, emtricitabine and raltegravir combination (8%). Conclusion: Effectiveness, efficiency and safety care quality indicators are mostly achieved. We can conclude that more resistance studies are required in the event of virological failure and we should improve treatment adherence records. References and/or Acknowledgements: www.gesida-seimc.org No conflict of interest.